The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Patricia M. Lorusso

Karmanos Cancer Institute

Detroit

Michigan 48201

USA

[email]@karmanos.org

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Karmanos Cancer Institute, Detroit, Michigan 48201, USA. 2005 - 2012
  • DO, Center for Experimental Therapeutics, Karmanos Cancer Institute/Wayne State University, 4100 John R. 2011
  • Phase I Clinical Trial Program, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, USA. 2000 - 2010

References

  1. Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432. LoRusso, P.M., Venkatakrishnan, K., Ramanathan, R.K., Sarantopoulos, J., Mulkerin, D., Shibata, S.I., Hamilton, A., Dowlati, A., Mani, S., Rudek, M.A., Takimoto, C.H., Neuwirth, R., Esseltine, D.L., Ivy, P. Clin. Cancer Res. (2012) [Pubmed]
  2. Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors. Lorusso, P., Shapiro, G.I., Hurwitz, H., Pilat, M.J., Chemidlin, J., Kollia, G., Syed, S., Fischer, B., Masson, E. Cancer Chemother. Pharmacol. (2011) [Pubmed]
  3. Clinical Development of Vascular Disrupting Agents: What Lessons Can We Learn From ASA404? Lorusso, P.M., Boerner, S.A., Hunsberger, S. J. Clin. Oncol. (2011) [Pubmed]
  4. Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study. Lorusso, P., Shields, A.F., Gadgeel, S., Vaishampayan, U., Guthrie, T., Puchalski, T., Xu, J., Liu, Q. Invest. New. Drugs (2011) [Pubmed]
  5. Translating clinical trials into meaningful outcomes. LoRusso, P.M., Schnipper, L.E., Stewart, D.J., Boerner, S.A., Averbuch, S.D., Wolf, W. Clin. Cancer Res. (2010) [Pubmed]
  6. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. LoRusso, P.M., Krishnamurthi, S.S., Rinehart, J.J., Nabell, L.M., Malburg, L., Chapman, P.B., DePrimo, S.E., Bentivegna, S., Wilner, K.D., Tan, W., Ricart, A.D. Clin. Cancer Res. (2010) [Pubmed]
  7. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics. LoRusso, P.M., Boerner, S.A., Seymour, L. Clin. Cancer Res. (2010) [Pubmed]
  8. Toward evidence-based management of the dermatologic effects of EGFR inhibitors. LoRusso, P. Oncology (Williston Park, N.Y.) (2009) [Pubmed]
  9. Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors. Lorusso, P., Heath, E.I., McGreivy, J., Sun, Y.N., Melara, R., Yan, L., Malburg, L., Ingram, M., Wiezorek, J., Chen, L., Pilat, M.J. Invest. New. Drugs (2008) [Pubmed]
  10. Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. LoRusso, P.M., Gadgeel, S.M., Wozniak, A., Barge, A.J., Jones, H.K., DelProposto, Z.S., DeLuca, P.A., Evelhoch, J.L., Boerner, S.A., Wheeler, C. Invest. New. Drugs (2008) [Pubmed]
  11. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. Lorusso, P.M., Adjei, A.A., Varterasian, M., Gadgeel, S., Reid, J., Mitchell, D.Y., Hanson, L., DeLuca, P., Bruzek, L., Piens, J., Asbury, P., Van Becelaere, K., Herrera, R., Sebolt-Leopold, J., Meyer, M.B. J. Clin. Oncol. (2005) [Pubmed]
  12. Oxaliplatin in tumors other than colorectal cancer. Lorusso, P.M. Oncology (Williston Park, N.Y.) (2000) [Pubmed]
 
WikiGenes - Universities